Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.34 AUD | 0.00% | -9.33% | +65.85% |
May. 01 | Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication | MT |
Apr. 22 | Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter | MT |
Sales 2022 | 6.47M 4.28M | Sales 2023 | 8.98M 5.95M | Capitalization | 24.06M 15.94M |
---|---|---|---|---|---|
Net income 2022 | -10M -6.63M | Net income 2023 | -13M -8.62M | EV / Sales 2022 | 4.48 x |
Net cash position 2022 | 9.56M 6.33M | Net cash position 2023 | 2.03M 1.35M | EV / Sales 2023 | 2.45 x |
P/E ratio 2022 |
-3.37
x | P/E ratio 2023 |
-1.46
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 95.78% |
1 week | -9.33% | ||
Current month | +1.49% | ||
1 month | +1.49% | ||
3 months | +74.36% | ||
6 months | +151.85% | ||
Current year | +65.85% |
Managers | Title | Age | Since |
---|---|---|---|
Nina Webster
CEO | Chief Executive Officer | - | 18-08-26 |
Hamish George
DFI | Director of Finance/CFO | - | 19-05-05 |
David Fuller
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nina Webster
CEO | Chief Executive Officer | - | 18-08-26 |
Hugh Alsop
BRD | Director/Board Member | - | 17-04-30 |
Mark Diamond
CHM | Chairman | - | 23-01-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 0.34 | 0.00% | 1,496,856 |
24-05-23 | 0.34 | 0.00% | 858,762 |
24-05-22 | 0.34 | -1.45% | 3,480,595 |
24-05-21 | 0.345 | -2.82% | 3,844,520 |
24-05-20 | 0.355 | -5.33% | 3,840,254 |
Delayed Quote Australian S.E., May 24, 2024 at 02:10 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+65.85% | 124M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- DXB Stock